Valuing Genzyme: Adding A Health Care Reform Premium
Executive Summary
As Sanofi-Aventis's board mulls whether to up its offer for Genzyme, Wall Street is busy crunching the numbers, and there are plenty of factors to consider. Sanofi’s now-public offer is $69 per share in cash, or a total of $18.5 billion for the company. That represents about a 40% premium to Genzyme Corp.’s share price as of mid-July, when Sanofi’s interest became apparent.
You may also be interested in...
Orphan Drug “Improvements” May Be Undercut By New Market Share Fees
The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.
Orphan Drug “Improvements” May Be Undercut By New Market Share Fees
The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.
Taking Lumps From Health Care Reform
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.